Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult patients with moderate-to-severe Sjogren’s disease, having previously been granted Breakthrough Therapy designation for the investigational therapy late last year. Currently, no advanced therapies are approved to treat this disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Big pharma fears drug price spikes in US-EU tariff spat, Reuters says
- Nanobiotix amends global licensing agreement with Janssen Pharmaceutica
- Big Pharma rejoins the mental health field, WSJ says
- Johnson & Johnson’s Strategic Shift to Comprehensive Procedural Solutions Drives Buy Rating
- Rallybio reports Q4 EPS (25c), consensus (30c)